top of page

Encyclopedia of Psychology

Addiction Severity and Level of Care: How Treatment Needs Are Assessed

3 days ago
25 min read

Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy

Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens

What addiction severity and level of care mean

An addiction severity assessment examines how substance use affects health, behavior, functioning, and safety, and what a person needs to recover or reduce harm. A level-of-care assessment translates that information into a recommendation about the clinical services, frequency of contact, monitoring, and treatment environment likely to be safe and effective. These decisions are connected, but they answer different questions. Diagnosis establishes whether a substance use disorder is present; diagnostic severity describes the number of relevant disorder criteria; level of care identifies the services required in the person's current circumstances. The American Society of Addiction Medicine (ASAM) describes this as individualized, multidimensional placement across a continuum of addiction care.

A person meeting criteria for a severe substance use disorder may be medically stable, strongly engaged in treatment, securely housed, and able to receive effective medications and frequent support as an outpatient. Another person with fewer substance use disorder symptoms may face a dangerous alcohol withdrawal syndrome, an unstable medical condition, or an immediate psychiatric crisis requiring hospital-level evaluation. The second person may need more intensive short-term services even though their diagnostic symptom count is lower. Care is selected by assessing the actual risks and treatment requirements in the present, not by assigning a permanent label of mild, moderate, or severe.

The contemporary clinical objective is to identify an effective and feasible setting that meets safety requirements, offers evidence-based treatment for the substance involved, and supports continuing care. The Fourth Edition of The ASAM Criteria describes dimensional admission decisions as identifying an appropriate level of care at which the person's needs can be addressed safely and effectively. Assessment remains a clinical process involving a trained professional, the patient, available collateral information with appropriate consent, and reassessment as circumstances change.

Three distinct questions: use, disorder, and treatment intensity

Substance use and risky use

Substance use means exposure to alcohol, nicotine, prescribed or nonprescribed psychoactive medications, or other drugs. Risky use refers to a pattern or circumstance that increases the probability of harm, including use in hazardous situations, hazardous interactions, or exposure to an unpredictable drug supply. Such behaviors can warrant advice, screening, prevention, or harm-reduction services without establishing the diagnosis of a substance use disorder. The everyday phrase substance misuse is used inconsistently and has less diagnostic precision than an explicitly described pattern of use and harm.

Substance use disorder and diagnostic severity

A substance use disorder is a clinical diagnosis involving a problematic pattern of use associated with impaired control, continued use despite harmful consequences, and other substance-specific features over the relevant diagnostic period. In DSM-5-TR, the familiar mild, moderate, and severe categories for most substance use disorders correspond to increasing numbers of applicable diagnostic criteria: two or three, four or five, and six or more. These counts summarize diagnostic features; they are not a direct measure of medical instability, likelihood of overdose, need for 24-hour nursing care, or the ability to participate in outpatient treatment. Diagnostic systems such as ICD-11 organize harmful substance-use patterns and dependence differently, and cross-system terminology should be identified rather than assumed interchangeable.

Tolerance and physical dependence are physiological adaptations. They may occur during appropriate prescribed medication treatment, and by themselves do not prove compulsive substance use or addiction. Withdrawal is an acute clinical phenomenon that varies widely by substance. The degree of withdrawal risk is central to immediate level-of-care assessment even when a patient's broader disorder history is incompletely established. Addiction is commonly used as a clinical and scientific term for compulsive substance use; its use should be connected to specific clinical definitions rather than treated as a numerical placement score.

Level of care and the intensity of services

A level of care describes an organized clinical service with a defined capacity: outpatient consultation and medication care; structured outpatient treatment several days a week; day-treatment or partial-hospital services; residential treatment with overnight support; medically monitored settings; and hospital-level management when acute medical or psychiatric instability demands it. Level of care also implies the program's actual staffing, medication availability, capacity to evaluate co-occurring conditions, emergency response, and continuity arrangements. Two programs described as residential may provide markedly different medical services, so their labels alone are insufficient for safe referral.

The central placement question is what care will meet the patient's assessed needs. A recommendation to use outpatient services does not mean a disorder is unimportant. A recommendation to use hospital services does not imply personal failure. Both are time-sensitive clinical judgments intended to match treatment resources to medical and psychosocial needs.

How a comprehensive assessment proceeds

First contact: establish immediate safety

Clinicians begin with medical and behavioral emergencies before conducting a lengthy diagnostic interview. They look for possible overdose, impaired breathing, altered consciousness, severe intoxication, withdrawal complications, seizures, delirium, cardiovascular instability, suicidal intent, acute psychosis, severe agitation, and injuries. Depending on the findings, emergency medical care may come before a routine addiction assessment. A patient who cannot participate meaningfully because of severe intoxication or delirium may require stabilization and later reassessment.

Possible opioid overdose with slowed or stopped breathing, unresponsiveness, or abnormal breathing requires immediate emergency services and naloxone when available. Naloxone is an emergency opioid overdose reversal medicine; its use is followed by emergency evaluation because further monitoring may be necessary. Seizures, severe confusion, or hallucinations during possible alcohol or sedative withdrawal, as well as chest pain or hyperthermia after stimulant use, likewise require urgent medical evaluation. The ASAM alcohol withdrawal guideline specifies escalation when severe symptoms or unstable vital signs develop; its purpose is to inform clinician-managed care, not home detoxification.

Clarify substances, timing, and patterns

A clinical history documents each substance used, routes of administration, timing of recent exposures, frequency, approximate pattern, and concurrent prescription and nonprescription medicines. It explores episodes of intoxication, overdose, withdrawal, periods of reduction or abstinence, previous treatments, and the patient's own description of what has helped. Multiple substances need explicit consideration because combined use can create risks that are not apparent from any one substance. Alcohol with sedatives, opioids with benzodiazepines, or other overlapping central nervous system depressants require particular attention to respiratory and sedation risks.

The source of information matters. Patients may be uncertain about the contents of an unregulated drug supply, especially where synthetic opioids or adulterants are possible. Clinicians therefore distinguish reported substance exposure from laboratory-confirmed exposure, and neither a negative nor positive toxicology result replaces the medical history. A single test is a snapshot with limitations in detection windows, specificity, interpretation, and clinical relevance. A respectful, confidential interview tends to yield more useful information than accusatory questioning.

Examine health, psychiatric conditions, and daily functioning

Assessment includes relevant cardiovascular, respiratory, hepatic, neurologic, infectious, obstetric, and pain conditions; medication interactions; cognition; mood and anxiety symptoms; psychosis; trauma-related symptoms; suicidal thinking; and functional capacity. Symptoms may predate substance use, emerge during intoxication or withdrawal, or represent overlapping conditions. Temporal history, repeated evaluation, and information from previous records help clinicians distinguish these possibilities. SAMHSA's Treatment Improvement Protocol 42 emphasizes integrated assessment for co-occurring mental and substance use disorders.

Social context is equally clinical. Housing stability, family conflict, violence exposure, childcare, employment schedules, legal obligations, transportation, access to food, and ability to obtain prescribed medication affect whether a care plan is workable. Strengths such as supportive relationships, personal routines, stable employment, and prior recovery skills are also assessed. A patient's treatment preferences, cultural context, and previous experience with care provide information about whether a proposed program will be usable, acceptable, and sustained.

Formulate a shared treatment plan

After immediate safety questions are addressed, clinician and patient identify priority needs and choose interventions that fit both clinical findings and realistic access. A person may need a medical evaluation, opioid use disorder medication, alcohol use disorder pharmacotherapy, psychotherapy, contingency management, case management, housing assistance, peer support, or a coordinated combination. Clinical decisions are documented with their reasons, alternatives, and indications for reassessment. This step prevents the common error of equating the name of a facility with a complete treatment plan.

The ASAM Criteria Fourth Edition: multidimensional placement

The American Society of Addiction Medicine released the adult Fourth Edition of The ASAM Criteria in 2023. It provides a widely used US framework for structuring assessments, recommending levels of addiction care, and specifying expected service capabilities. Adoption and implementation vary by region, insurer, program, and patient group. Its core concepts are clinically informative internationally, while administrative eligibility and service names remain local. The following overview explains public-facing dimensions and principles without reproducing proprietary scoring instruments or admission algorithms.

Dimension 1: intoxication, withdrawal, and addiction medications

This domain concerns current intoxication, predicted or emerging withdrawal complications, and needs related to addiction medication. A clinician asks whether symptoms can be managed without round-the-clock observation, whether urgent stabilization is required, and whether a proposed service can actually initiate or continue the medication that the patient needs. The consequences vary by substance. Alcohol and benzodiazepine withdrawal can be medically dangerous; opioid withdrawal is distressing and can create important medical risks in vulnerable patients, whereas opioid overdose can rapidly suppress breathing. Safe opioid treatment includes assessment for access to evidence-based medications rather than treating withdrawal relief as a definitive recovery intervention. The CDC's opioid use disorder treatment guidance links medication treatment to reduced overdose and mortality risk and warns against withdrawal management alone as opioid use disorder treatment.

Dimension 2: biomedical conditions

Medical comorbidity changes placement when it limits stability or requires services not available in a proposed program. Examples include uncontrolled seizures, severe liver complications, pregnancy-related concerns, serious infection, poorly controlled diabetes, impaired mobility, or significant cardiopulmonary disease. Clinical urgency follows the actual condition, not its mere presence. A stable chronic illness managed in primary care may coexist with outpatient addiction treatment, while an acute complication demands a setting with greater medical capability.

Dimension 3: psychiatric and cognitive conditions

The clinician considers depression, psychosis, mania, severe anxiety, suicidality, trauma-related symptoms, cognitive impairment, delirium, and the patient's ability to understand and participate in treatment. Psychiatric symptoms have to be assessed for immediate safety and for the intensity of integrated mental health care required. The presence of a co-occurring diagnosis alone does not automatically determine inpatient placement; acute danger, impaired judgment, inability to care for basic needs, and program capability are pivotal. Reassessment after intoxication or withdrawal can clarify symptom patterns while leaving urgent safety treatment uninterrupted. SAMHSA TIP 42 provides the broader scientific and service-system context for co-occurring disorders.

Dimension 4: substance use-related risks

This domain concerns the likelihood and potential consequences of continued risky substance use and related behaviors under current conditions. Clinicians consider recent overdose, exposure to potent opioids, impaired control, use associated with injury, difficulty following safer-use plans, and the effects of cues or high-risk settings. A risk profile must be specific: nonfatal overdose, recurrent intoxication while driving, and return to use after leaving a protected setting imply different safety responses. Substance-use risk is also dynamic. The same person may need a more structured setting during a high-risk transition and a less intensive setting once support and treatment are established.

Dimension 5: recovery environment interactions

The treatment environment may facilitate or obstruct recovery. Housing insecurity, violence, coercion, limited privacy for medication, transportation barriers, unstable access to food, and the availability of social support can directly affect treatment participation and safety. Assessment should evaluate how the individual and environment interact rather than mark an entire neighborhood or family as intrinsically risky. Recovery housing, outreach, practical assistance, or a change in appointment format can sometimes reduce environmental risk without requiring medical hospitalization. A supportive living situation also cannot compensate for an acute medical emergency.

Dimension 6: person-centered considerations

The Fourth Edition gives explicit attention to patient preferences and feasible engagement through person-centered considerations. ASAM's assessment materials explain that clinical risk assessment informs the recommended care level, while discussion with the patient helps determine a level they can and will engage in. This incorporates logistical barriers, culturally appropriate options, treatment goals, and shared decision-making. The current edition no longer uses readiness to change as its own separate dimension: motivation and readiness inform clinical understanding and the design of services across the assessment. This is an important difference from descriptions of the older Third Edition that remain common online.

These dimensions work together. They are not six independent symptoms of addiction, and counting elevated domains is not an established substitute for proper clinical decision-making. The result should be a defensible recommendation tied to particular services and risks, not a mechanical average of unrelated difficulties.

Three assessment stages, each with a different purpose

The ASAM Fourth Edition Assessment Guides distinguish an initial level-of-care assessment, a fuller treatment-planning assessment, and reassessments during care. The first collects sufficient information to select an appropriate service, even when performed during an intake call or before admission. The next explores the biopsychosocial picture in greater depth and translates it into a personalized treatment plan. Later reassessments monitor change, revise interventions, and support decisions to increase, reduce, or transfer intensity.

This staged structure resolves a practical tension. Waiting for every laboratory result, historical record, or lengthy psychosocial inventory can delay urgent care; deciding everything on a rapid screening questionnaire can overlook important needs. A focused safety and placement evaluation makes timely entry possible, followed by deeper assessment and revision. If a patient reports new severe symptoms, becomes intoxicated, experiences overdose, or develops suicidal intent, immediate reevaluation takes precedence over a scheduled review.

Which instruments help, and what each actually measures

Brief screening instruments

Screening identifies who may need additional assessment. Instruments such as AUDIT-C for unhealthy alcohol use, DAST-10 for drug-related problems, and WHO ASSIST for substance involvement serve different populations and purposes. Their results can inform referral or the clinical interview, but they do not themselves establish the full diagnosis, specify a level of residential care, or reliably predict a complicated withdrawal course in every patient. A screening score can be affected by the substance involved, the recall period, stigma, literacy, and what the respondent understands about use.

Diagnostic interviews and symptom counts

A clinician evaluates applicable diagnostic criteria, their duration and clinical significance, and possible alternatives or co-occurring explanations. DSM-5-TR symptom-count severity helps describe disorder burden; ICD-11 classification has its own categories. Diagnostic criteria help select appropriate disorder-specific treatment, but they cannot by themselves decide whether outpatient monitoring, 24-hour structured treatment, or an emergency department is appropriate.

Addiction Severity Index and functional assessment

The Addiction Severity Index (ASI) is a multidomain instrument examining substance use together with medical, employment, legal, family/social, and psychiatric functioning. The ASI-6 has research support for multiple domain scales, including important differences in psychometric performance across domains. It is useful for understanding problems and tracking outcomes, yet an ASI composite or recent-status score is not synonymous with ASAM level-of-care placement. The validation study for ASI-6 recent status scores found stronger concurrent validity for several domains and weaker evidence for some legal and family-related scales. No single functional score substitutes for an emergency examination or a multidimensional admission decision.

Withdrawal and acute-risk assessments

Validated withdrawal measures can support clinician monitoring when used in appropriate populations and settings. However, observed withdrawal severity is not identical to predicted risk of severe complications, and a symptom scale does not overrule a history of withdrawal seizures, delirium, severe medical illness, or unstable vital signs. ASAM's alcohol withdrawal management guideline emphasizes clinical evaluation and ongoing monitoring. For benzodiazepines, the 2025 joint practice guideline recommends individualized, supervised decisions and avoidance of abrupt discontinuation in physically dependent patients.

Urine and other drug testing

Biological testing may assist in evaluating recent exposure, adherence, or exposure to additional substances where results will change care. Interpretation depends on the specimen, assay, detection period, cross-reactivity, and the clinical question. Some drugs may not be detected by routine screens. Positive tests do not automatically establish current impairment or a substance use disorder; negative tests cannot prove an absence of recent use. Drug testing should be explained and used in a manner that supports clinical decisions and trust, including appropriate informed consent and privacy safeguards.

The care continuum: what increasing intensity provides

Regular outpatient care

Outpatient care can include medical appointments, addiction medication, individual or group psychotherapy, case management, primary care integration, family interventions, and periodic monitoring. It is suitable when clinically important needs can be addressed without constant on-site supervision. Its strength is continuity with ordinary living circumstances: people can maintain employment, education, caregiving, and supportive routines while receiving treatment. Outpatient services vary greatly in quality and capabilities, especially access to effective pharmacotherapy and rapid responses to changes in risk.

Intensive outpatient programs

Intensive outpatient treatment offers a more structured schedule of therapeutic services while the patient lives in the community. It may combine evidence-based behavioral treatments, medical visits, psychiatric care, relapse-response planning, and recovery support. The relevant question is whether the additional frequency and coordination address the person's problems, not whether a fixed number of sessions signals greater commitment. A review by McCarty and colleagues found that, for many studied adults who did not require 24-hour monitoring, intensive outpatient care achieved substance-use outcomes comparable to inpatient or residential programs. Those findings reflect older studies with varying definitions of services and do not apply indiscriminately to severe acute withdrawal or medically unstable patients.

Partial hospitalization and high-intensity ambulatory care

Partial-hospital or day-treatment services offer several hours of organized care on many days, often with access to coordinated medical and psychiatric support. The patient ordinarily sleeps elsewhere. These settings may provide more clinical contact than standard intensive outpatient programs and can be used when symptoms and functional difficulties warrant high daytime structure without continuous overnight medical supervision. Program names differ across health systems, and actual staffing and availability should be checked before recommending them.

Residential treatment

Residential addiction care provides a structured living environment with on-site support and treatment activities. It can help when environmental instability, repeated loss of engagement, and intensive therapeutic needs cannot be adequately addressed through ambulatory options. A residential program may be clinically managed with limited medical capacity, or it may have enhanced capacity for medical and psychiatric monitoring. A facility offering lodging does not necessarily provide comprehensive withdrawal management, medication for opioid use disorder, or hospital-level emergency care. Placement requires verification that the program can deliver indicated services and coordinate transitions after discharge.

Medically monitored and hospital-level care

Settings with intensive medical supervision are appropriate when withdrawal, intoxication, physical illness, or psychiatric instability requires monitoring and intervention beyond ambulatory or clinically managed residential capacity. Hospital-level care may be needed for life-threatening complications, severe medical instability, serious overdose, or acute psychiatric emergencies. The ASAM Fourth Edition distinguishes treatment intensities by actual clinical service capabilities and also includes variants intended to address co-occurring psychiatric or biomedical needs. The clinician should recommend the service that fits the present risk and arrange a transfer as necessary rather than interpreting a level label as a guarantee of safety.

Long-term remission monitoring and continuing care

Treatment intensity can decrease while care continues. The Fourth Edition recognizes monitoring for stable remission within the broader continuum, acknowledging that people may still benefit from follow-up, recovery management, and ongoing medication even after acute symptoms have improved. Continuing support can include addiction medication, periodic assessment, peer support, primary care, recovery housing, employment assistance, and reengagement after changing needs. A patient who no longer requires residential treatment may still need clinically meaningful long-term care.

How the choice is made in practice

A sound recommendation starts by identifying which conditions require which services. For example, if severe alcohol withdrawal is plausible, the plan prioritizes medically appropriate assessment and management, with the care setting chosen for monitoring and emergency capability. If a person with opioid use disorder is stable but faces high overdose risk, rapid access to medication treatment and naloxone may be more important than a prolonged period of medication-free residential care. If a person has active psychosis, suicidal intent, or delirium, immediate psychiatric or medical stabilization changes the priority. These are examples of decision logic, not self-diagnostic rules.

The clinician then checks whether a candidate treatment program offers the recommended therapies. Availability of buprenorphine or methadone, medical evaluation, alcohol use disorder medications, psychiatric treatment, trauma-informed approaches, evidence-based behavioral programs, accessible appointments, and appropriate follow-up all matter. A care recommendation that cannot be implemented because medication is unavailable or because the patient cannot reach the program calls for active problem solving and alternative referral, not a conclusion that the patient lacks motivation.

The least intensive safe and effective level is a useful organizing principle, but it is interpreted with clinical judgment. Decisions must address what could reasonably happen between appointments, which supports are available, and how quickly the care team can respond. A person who has experienced repeated overdose may need intensive harm-reduction and medication support while receiving outpatient care. Another may need brief hospital stabilization followed by ongoing outpatient treatment. Treatment intensity, living environment, and the pharmacologic strategy can be adjusted independently when necessary.

Why placement cannot be determined by one number

It is tempting to construct a single addiction score by adding substance-use quantity, withdrawal severity, psychiatric symptoms, and social adversity. This loses the clinical meaning of different risks. Severe withdrawal and housing insecurity are both important, but one can require immediate medical management while the other may respond to housing support and longitudinal care. The highest-risk domain can govern immediate safety even when other domains show little impairment. Conversely, several moderate needs can interact to make a program insufficient even if no individual domain appears catastrophic.

Clinical prediction also has uncertainties. Self-report can be incomplete, conditions fluctuate, drug content may be unknown, and prior records may be unavailable. Structured assessment improves consistency but remains a decision aid. It should be paired with medical assessment, careful documentation, a contingency plan, and opportunities to revise decisions. A recommendation is stronger when it explains the specific harms it intends to prevent and how the proposed services address them.

What research says about treatment matching

Evidence for multidimensional assessment

The research foundation for multidimensional placement includes validation and implementation studies as well as expert consensus. ASAM's evidence overview reports evaluations of feasibility, reliability, convergent validity, and treatment matching. Such research supports structured evaluation as a means of making clinical needs visible and treatment decisions more consistent. The evidence is not equivalent to a randomized demonstration that each current Fourth Edition admission recommendation always yields better outcomes than every alternative for every substance or population. Changes introduced in 2023, including updated dimensions and implementation methods, require ongoing prospective evaluation.

One earlier observational study of 248 adults entering alcohol treatment reported worse drinking outcomes when some patients received regular outpatient care despite a recommendation for intensive outpatient services, whereas more intensive care than recommended did not show better outcomes. This finding supports the practical importance of avoiding undertreatment, but the study examined an earlier version of placement criteria, was not a trial of the Fourth Edition, and cannot eliminate confounding from patient selection and services received. See the predictive validity study for the relevant design and limitations.

Intensive outpatient versus inpatient or residential care

A systematic evidence review of studies published largely before 2013 found substantial improvements in alcohol and drug use outcomes among adults treated in intensive outpatient or residential/inpatient settings, often with no major differences in measured outcomes between settings. McCarty and colleagues drew conclusions for individuals who did not require acute medical detoxification or round-the-clock supervision. Variation in treatment content, patient selection, outcome definitions, and historical service models limits extrapolation. The review supports the effectiveness of ambulatory alternatives for appropriate patients, not a universal equivalence of all levels of care.

Matching services to the disorder being treated

Setting alone does not establish treatment quality. For opioid use disorder, the CDC identifies buprenorphine, methadone, and naltrexone as approved medication options and associates medication treatment with lower overdose and mortality risk; opioid withdrawal management without ongoing medication treatment increases the risk associated with return to use. For stimulant use disorder, the ASAM and AAAP clinical guideline identifies contingency management as a central evidence-based behavioral intervention and considers other psychosocial therapies and clinical risks. For alcohol use disorder, effective medications and behavioral support may be delivered through several care models. A placement system should safeguard access to effective treatment rather than merely increase supervision hours.

Established, heterogeneous, and limited evidence

Established clinical foundations include urgent stabilization of life-threatening intoxication or withdrawal, individualized assessment of co-occurring conditions, evidence-based medication for opioid use disorder, and the use of appropriate psychosocial treatments according to substance and circumstances. Supported but heterogeneous findings include the comparative effectiveness of intensive outpatient and residential care across selected adult populations and models. More limited or evolving evidence concerns exact individualized predictions of the best care setting, the incremental benefit of each Fourth Edition decision rule, and long-term comparative outcomes for many specific groups. The level-of-care recommendation is therefore an evidence-informed judgment that remains revisable.

Medical emergencies and conditions that change placement immediately

Alcohol withdrawal

Alcohol withdrawal may progress to seizures, delirium, and severe physiological instability. Clinicians assess prior withdrawal complications, current signs, co-occurring illness, other sedative exposure, available monitoring, and the time course of recent use. A patient with warning signs of complicated withdrawal requires emergency evaluation. The ASAM guideline explains why withdrawal management must be integrated with subsequent treatment for alcohol use disorder. A person's prior experience of a mild withdrawal episode does not guarantee that a future episode will remain mild.

Benzodiazepine dependence and withdrawal

Prolonged benzodiazepine exposure can lead to physical dependence even in patients using medication as directed. Abrupt cessation in a dependent patient can precipitate serious withdrawal, including seizures. The 2025 multisociety guideline recommends clinical risk–benefit evaluation, shared decision-making, individualized tapering, and a higher level of care when risks cannot be managed safely as an outpatient. The existence of physical dependence does not by itself prove benzodiazepine use disorder. Any decision to change prescribed sedatives should be made with the treating clinician.

Opioid overdose and ongoing opioid treatment

Opioid overdose can cause fatal respiratory depression. Unresponsiveness, slow or absent breathing, or signs of severe oxygen deprivation require emergency services and prompt naloxone when available. When the immediate crisis is treated, level-of-care assessment should include access to evidence-based opioid use disorder medication, overdose prevention, co-occurring medical care, and a rapid follow-up plan. The CDC's clinical guidance cautions against presenting detoxification alone as adequate treatment for opioid use disorder.

Stimulant toxicity and psychiatric crisis

Stimulant intoxication may involve chest pain, marked agitation, hyperthermia, arrhythmias, seizures, severe hypertension, or psychotic symptoms. The ASAM and AAAP guideline advises attention to cardiovascular and other acute complications and appropriate escalation to medical care. Severe depression, suicidality, violent behavior, delirium, and loss of capacity to protect oneself can also require emergency psychiatric assessment. These decisions depend on current clinical danger and capacity for supervision, not on stigmatizing assumptions about people who use stimulants.

Co-occurring conditions and complex treatment needs

Many patients have psychiatric symptoms, chronic pain, infectious illness, or other conditions alongside substance use problems. Coordinated treatment may be essential when one disorder worsens the other or interferes with care. For example, treating substance use while ignoring an acute mood disorder with suicidal intent creates a major safety gap. Similarly, managing depression while leaving opioid use disorder untreated misses a major contributor to morbidity. Integrated services coordinate diagnostic assessment, medication decisions, psychotherapy, physical health care, and follow-up. SAMHSA TIP 42 outlines coordinated and integrated approaches for co-occurring disorders.

People with cognitive impairments may need simplified information, repeated explanation, supported decision-making, adapted therapies, or involvement of an authorized support person. Chronic pain warrants a plan that evaluates function and safety without assuming that pain reporting demonstrates addiction. Infectious diseases and pregnancy require coordination with the appropriate specialties. The right level of care is a system capability question: who can deliver these treatments together, with reasonable continuity and safety?

Adolescents, pregnancy, older adults, and other populations

Assessment frameworks developed for adults should be applied cautiously to younger people. Development, family context, schooling, consent rules, and protective services may alter the meaning of a risk or a feasible treatment plan. ASAM released a dedicated Fourth Edition volume for adolescents and transition-aged youth in 2026, emphasizing youth-guided and family-informed treatment, developmental needs, and a youth-oriented continuum. A minor's care plan should use applicable age-specific standards and local legal protections rather than simply transplanting adult service expectations.

During pregnancy, an integrated obstetric and addiction assessment is needed because maternal health, fetal health, medication continuity, and access to prenatal care affect treatment. For opioid use disorder during pregnancy, ACOG recommends opioid agonist treatment with methadone or buprenorphine rather than medically supervised withdrawal as the routine alternative, owing to high recurrence risk after withdrawal. This is a substance-specific clinical recommendation and should be managed with qualified pregnancy and addiction clinicians.

Older adults may have reduced physiological reserve, polypharmacy, falls, cognitive changes, or chronic organ disease that change the risks of intoxication and withdrawal. People experiencing homelessness, violence, disability, language barriers, or discrimination may need accommodations and service coordination. These factors should be addressed as practical care needs and health-equity concerns. They should never become proxies for assuming low motivation, criminality, or a fixed clinical prognosis.

Patient preferences, practical feasibility, and equitable access

Shared decision-making is a clinical requirement for a treatment plan that can work in real life. Clinicians should explain the assessment findings, proposed level of care, expected treatments, foreseeable risks, alternatives, and arrangements for transfer or follow-up. The patient can explain childcare obligations, financial pressures, travel constraints, cultural expectations, trauma-related concerns, and preferences for medication or counseling. Such information can change which safe options are feasible or what support must accompany a recommendation.

Health systems can create mismatches. A region may lack a program capable of managing complicated withdrawal; an insurer may authorize a different setting from the treating team's recommendation; a residential program may decline patients receiving an indicated addiction medication. These barriers do not reduce clinical need. Documentation should distinguish the medically recommended level from the level actually available, identify the gap, and arrange a safe, practical alternative or escalation when possible. Continuity across organizations and an accessible follow-up appointment are often as consequential as the initial intake decision.

When and why the level of care changes

Level-of-care assessment is repeated because clinical risk and functioning change. Patients may require temporary escalation after overdose, renewed withdrawal risk, acute medical illness, worsening suicidality, or loss of a safe living environment. Conversely, stabilization with medication, improving coping skills, consistent participation, medical recovery, and a supportive environment can justify a transition to a less intensive setting. A transfer should preserve medications, vital clinical information, safety planning, and connection with the next team. Abrupt discharge without follow-up can create avoidable risk.

Recurrence of substance use calls for reassessment of treatment fit, environmental exposures, medication access, and immediate safety. It is clinical information about what may need to change. Recovery measures can include substance use patterns, overdose events, attendance, physical and psychological health, housing stability, work or educational functioning, social relationships, and the patient's goals. A single negative test result or short episode of abstinence provides only partial information about recovery.

Illustrative clinical scenarios

Scenario 1: severe diagnosis, outpatient treatment is viable

A person meets several criteria for opioid use disorder but has no acute intoxication, lives in stable housing, is willing to start evidence-based medication, and can attend follow-up. A clinician may be able to arrange outpatient medication care with overdose prevention and psychosocial services. The substantial diagnostic burden establishes the importance of treatment while current stability and accessible services make ambulatory care realistic. If overdose risk or functioning changes, reassessment is warranted.

Scenario 2: fewer symptoms, urgent withdrawal evaluation

A person reports recent heavy alcohol exposure, has a history of withdrawal seizures, and now presents with confusion or unstable vital signs. Regardless of how many disorder criteria are documented during the encounter, emergency medical assessment takes priority. Subsequent treatment planning addresses ongoing alcohol use disorder care as well as immediate withdrawal management. This scenario illustrates why a diagnostic symptom count cannot be substituted for a safety evaluation.

Scenario 3: environmental instability increases support needs

A person has a stimulant use disorder, repeated loss of housing, and difficulty attending conventional appointments, but has no acute medical instability. A multidisciplinary assessment may prioritize a program with case management, accessible contingency management, coordinated medical care, transportation support, and housing assistance. Residential treatment could be considered when clinically appropriate, but its benefit depends on the services it provides and the person's situation. Housing instability is a treatment barrier to address, not a diagnosis in itself.

Scenario 4: co-occurring depression changes the care plan

A patient seeking addiction treatment reports severe depression and active suicidal intent. Immediate psychiatric safety assessment and stabilization become essential, potentially in an emergency or hospital setting. Once stabilized, the ongoing addiction plan needs to address both conditions and maintain continuity. The eventual treatment level depends on the reassessed risks and program capabilities, not merely on whether two diagnoses coexist.

Common misconceptions about addiction severity and placement

The phrase severe addiction often evokes residential treatment, but diagnostic severity and placement intensity are separate clinical variables. Inpatient or residential treatment is not automatically superior to evidence-based outpatient treatment for every patient; outcomes depend on selection, treatment content, safety needs, engagement, and continuity. A brief withdrawal episode is not complete addiction treatment. A patient taking methadone or buprenorphine remains eligible for recovery-oriented care; the presence of an effective medication is a treatment asset. A change in level of care reflects changing clinical needs, and receiving a less intensive service is not evidence that a person is being abandoned.

Assessment is also not a one-time gate controlled entirely by screening software. Patient choice, current medical conditions, social resources, and clinical judgment remain essential. The strongest decisions state what needs to be treated, what risks demand special monitoring, why a particular program can provide the necessary care, and when the decision will be revisited.

Frequently asked questions

Is a severe substance use disorder always treated in residential care?

No. DSM-5-TR severity describes diagnostic features, whereas placement depends on present medical and psychiatric safety, substance-use risks, environmental circumstances, service capability, and personal feasibility. Effective addiction medication and coordinated outpatient follow-up may be appropriate for some people with severe disorders. Other people need round-the-clock care because of acute complications.

Can a person with a mild diagnosis require hospitalization?

Yes. A medically dangerous withdrawal syndrome, overdose, acute cardiac complication, delirium, or serious suicidal crisis can require urgent hospital evaluation irrespective of diagnostic symptom count. Emergency triage and the diagnosis of an ongoing substance use disorder answer distinct questions.

What is the difference between screening and a level-of-care assessment?

Screening quickly identifies potential substance-related risk or problems needing evaluation. A level-of-care assessment examines multiple clinical dimensions to determine the services and supervision needed. A fuller treatment-planning assessment then develops individualized interventions and recovery supports. ASAM's current assessment guidance explicitly separates these functions.

Is the Addiction Severity Index the same as the ASAM Criteria?

No. The ASI measures difficulties and functioning across multiple areas of life, whereas the ASAM Criteria organize a clinical process for recommending treatment intensity and service capabilities. An ASI assessment can inform treatment planning, but it does not independently replace an ASAM-informed placement assessment.

Is detoxification the first necessary step for everyone?

No. The need for withdrawal management depends on substance, exposure, symptoms, physiological dependence, and medical risks. Some patients begin ongoing medication and behavioral care without a separate residential detoxification episode. For opioid use disorder, withdrawal management alone is specifically discouraged by CDC guidance because of the increased risk associated with return to use.

Does an intensive outpatient program work as well as inpatient treatment?

Evidence from older comparative studies indicates similar substance-use outcomes for many selected adults who do not require 24-hour medical supervision. That evidence cannot justify intensive outpatient treatment for every medically or psychiatrically unstable person and does not establish that all programs are equivalent. The appropriate decision depends on individual needs and the actual services being compared.

Who decides when the level of care should change?

A qualified clinical team reassesses risk, treatment response, functioning, and the capacity of available services, and discusses options with the patient. New emergencies require immediate action; planned transitions should coordinate medication, follow-up, supports, and continuity. Local professional and funding rules influence how placement decisions are implemented.

What if the recommended service is unavailable?

The clinical recommendation should remain documented. The care team should discuss feasible alternatives, urgent safety needs, available services, medication access, and a plan to reassess or transfer when a more suitable setting becomes available. Practical barriers call for coordinated problem solving rather than a change in diagnostic meaning.

Clinical synthesis

Addiction severity assessment and level-of-care selection are parts of one patient-centered clinical process with different purposes. Diagnostic criteria identify the substance use disorder and describe its features. A multidimensional evaluation considers current intoxication and withdrawal, biomedical and psychiatric needs, risks linked to substance use, environmental circumstances, and what services a person can realistically engage in. The treatment setting follows from those findings and from the program's actual ability to provide evidence-based care. Timely emergency evaluation, appropriate medication, supportive therapeutic relationships, and regular reassessment keep placement responsive to changing needs across the course of recovery.

Related Articles

Inpatient vs Outpatient Addiction Treatment: Matching Care to Needs — clinical indications and outcomes for residential, inpatient, and ambulatory addiction care.

Addiction Treatment: Evidence-Based Options and How Care Works — comparative behavioral, medication, medical, and recovery-oriented approaches to addiction care.

References

  • American College of Obstetricians and Gynecologists. (2017). Opioid Use and Opioid Use Disorder in Pregnancy. Committee Opinion No. 711. Official guidance.

  • American Society of Addiction Medicine. (2020). The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. Official guideline.

  • American Society of Addiction Medicine. (2023). The ASAM Criteria, Fourth Edition: Adults. Official Fourth Edition overview.

  • American Society of Addiction Medicine. (2024–2026). Fourth Edition Assessment Guides. Official implementation guidance.

  • American Society of Addiction Medicine. (2026). The ASAM Criteria, Fourth Edition: Adolescents and Transition-Aged Youth. Official volume overview.

  • American Society of Addiction Medicine and American Academy of Addiction Psychiatry. (2024). The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder. Journal of Addiction Medicine, 18, 1–56. DOI.

  • Centers for Disease Control and Prevention. (2024). Opioid Use Disorder: Treating. Official clinical guidance.

  • Magura, S., Staines, G. L., Kosanke, N., Rosenblum, A., Foote, J., DeLuca, A., and Bali, P. (2003). Predictive validity of the ASAM Patient Placement Criteria for naturalistically matched versus mismatched alcoholism patients. PubMed.

  • McCarty, D., Braude, L., Lyman, D. R., Dougherty, R. H., Daniels, A. S., Ghose, S. S., and Delphin-Rittmon, M. E. (2014). Substance Abuse Intensive Outpatient Programs: Assessing the Evidence. Psychiatric Services, 65(6), 718–726. DOI.

  • McLellan, A. T., Cacciola, J. S., Alterman, A. I., Rikoon, S. H., and Carise, D. (2006). The Addiction Severity Index at 25: Origins, Contributions and Transitions. American Journal on Addictions, 15(2), 113–124. DOI.

  • Rikoon, S. H., Cacciola, J. S., Carise, D., Alterman, A. I., and McLellan, A. T. (2006). Predicting DSM-IV dependence diagnoses from Addiction Severity Index composite scores. DOI.

  • Substance Abuse and Mental Health Services Administration. (2020). Substance Use Disorder Treatment for People With Co-Occurring Disorders. Treatment Improvement Protocol 42. Official NCBI Bookshelf edition.

  • Substance Abuse and Mental Health Services Administration. (2021; updated online 2024). Medications for Opioid Use Disorder. Treatment Improvement Protocol 63. Official guidance.

  • U.S. Multisociety Benzodiazepine Tapering Guideline Committee. (2025). Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits. Journal of General Internal Medicine. DOI.

  • World Health Organization. (2024). Clinical Descriptions and Diagnostic Requirements for ICD-11 Mental, Behavioural and Neurodevelopmental Disorders. Official publication.

 
 
bottom of page